KRAS Test
KRAS mutations are detected in approximately 30% to 40% of all patients with colorectal cancer (CRC). The KRAS Test is a highly sensitive and specific mutation analysis that guides oncologists as they seek to determine whether a patient will respond to drugs that target the Epidermal Growth Factor Receptor (EGFR). Clinical guidelines now recommend that all patients diagnosed with metastatic colorectal cancer have their tumor tested for KRAS before starting anti-EGFR therapy.
- bioTheranostics KRAS test identifies 7 mutations in codons 12 and 13
- bioTheranostics KRAS testing detects >95% of all known and clinically relevant mutations
- Test technology has been validated in targeted population to investigate safety, efficacy of cetuximab, panitumumab
Recent studies suggest that patients who have KRAS mutations detected in codon 12 or 13 do not benefit from anti-EGFR monoclonal antibody therapy.
© 2012 bioTheranostics. All rights reserved.
+1 (877) 886-6739 client services
+1 (877) 886-6739 client services
